NDAINTRAMUSCULARFOR SUSPENSION, EXTENDED RELEASE
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
RISVAN (risperidone) by PharmaIN. Approved for schizophrenia, schizoaffective disorder, bipolar disorder and 1 more indications. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RISVAN (risperidone) is an extended-release intramuscular suspension approved in March 2024 for schizophrenia, schizoaffective disorder, bipolar disorder, and psychotic disorders. It is a second-generation antipsychotic that works through dopamine D2 and serotonin 5-HT2A receptor antagonism. The IM formulation provides prolonged therapeutic coverage with improved patient adherence compared to oral alternatives.
Growth5.1 years to LOE
Early-stage growth product with minimal competitive pressure offers rare opportunity to build market presence and establish brand positioning before competitive response.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (4)
Worked on RISVAN at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.